Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 The Lancet I was so excited to see that there was finally a study evaluating abx-loaded bone cement!... then I see that it was just low-dose vs high-dose cement. 😞 If you're setting up an RCT, how in the world is "standard-of-care" not cement without abx at all?!

Collectively, 1000s of hours of work. Very proud to present to you all the second WikiGuidelines for the diagnosis and management of infective endocarditis. Todd C. Lee Brad Spellberg Jonathan Ryder, MD Steven Tong and many many many others Thank you

sciencedirect.com/science/articl… 🔥 New article from Gemma K Reynolds Beatrice Sim monica slavin Ben Teh Systematic review and meta-analysis of infections in HM patients treated with CAR-T. Bacterial more common than viral or fungal post CAR-T, 17% developed serious infection.

Excited to share that our next TransplantID Journal Special Edition - on Infections in Patients Undergoing Hematopoietic Cell Transplant. Amazing reviews on all key aspects of HSCT ID. onlinelibrary.wiley.com/toc/13993062/c…

Dr Abby Douglas will use her NHMRC Investigator Grant to study new cutting-edge diagnostic tests and clinical trials of #antibiotic cessation to reduce #antibiotics use and improve patient care. Read more: petermac.org/about-us/news-…

Do clinical trials of antimicrobial agents give clinicians the information they need in order to change guidelines and revise their prescribing patterns? A thread on a new way to analyze clinical trial results

We are delighted to have Australian Society for Antimicrobials ASA President A/Prof Louise Cooley and Vice-President Dr Iain Abbott present a 2-part series on #antimicrobial susceptibility testing for our March NCAS Seminar Series. Register here: lnkd.in/gJZVD2GE

Collaborative, interprofessional (partnered) medication charting and prescribing models are being introduced at many Australian hospitals. These models reduce the risk of medication errors at admission and discharge, and reduce patients’ length of hospital stay. One high-risk

Just out #AACJournal ASM. HCO3 Resensitisation of MRSA to B-lactam and outcomes in the CAMERA2 trial journals.asm.org/doi/10.1128/aa… First author: Neta Petersiel In memorandam of Arnold Bayer Joshua Davis Benjamin Howden UniMelb MDHS Doherty Institute Stefano Giulieri Thread

Gus Hamilton Jason Roberts @jpogue1 David Paterson More & more trials are like this, right? To prove benefit for a small group you can’t readily identify you must apply an intervention broadly & 🙏 to stats Gods. Then attention shifts to better tools for identifying the group likely to benefit, cost-benefit, and reducing costs…

Similar to our usual practice of starting broad and de-escalating as microbiology comes through, it would make sense to start with continuous infusion, and 'de-escalate' to other drugs / intermittent dosing if the infecting organism / MIC / renal clearance allows

Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 So no stat significant difference in: - rate of FN - microbiologically confirmed infection - bacteraemia - hospitalisation - ICU admission - 30d mortality And they paint as a positive study? Also, p7 I think they have their FQ resistance % the wrong way around 7.2 vs 20.8